Potential role of cannabinoids in Parkinson's disease

Drugs and Aging

Volumn 16, Issue 6, 2000, Pages 391-395

  Ševčík, Jan ^a   Mašek, Karel ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID;

BASAL GANGLION; DOPAMINERGIC NERVE CELL; EDITORIAL; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0033920369     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016060-00001     Document Type: Editorial

References (41)

1. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardmann JG, Goodman Gilman A, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 503-19
2. Gerlach M, Riederer P, Youdim MBH. Neuroprotective therapeutic strategies: comparison of experimental and clinical results. Biochem Pharmacol 1995 Jun; 50 (1): 1-16
3. Youdim MBH, Riederer P. Understanding Parkinson's disease. Sci Am 1997 Jan; 276 (1): 38-45
4. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990 Dec; 55 (6): 2142-5
5. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998 Sep; 44 (3 Suppl. 1): S110-4
6. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994 Mar 3; 330 (9): 613-22
7. Akaike A. Glutamate neurotoxicity and neuroprotective factors. Nippon Yakurigaku Zasshi 1994 May; 103 (5): 193-201
8. Cohen G, Werner P. Free radicals, oxidative stress and neurodegeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia (PA): W.B. Saunders, 1994: 139-61
9. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992 Dec; 32 (6): 804-12
10. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990 Oct; 40 (10 Suppl. 3): 32-7
11. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl. 1991; 136: 6-15
12. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993 Jan 21; 328 (3): 176-83
13. Mechoulam R. The pharmacohistory of Cannabis sativa, In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC, 1986: 1-19
14. Gowers, WR. A manual of diseases of the nervous system. Vol. II. London: Churchill, 1888
15. Annas GJ. Reefer madness: the federal response to California's medical-marijuana law. N Engl J Med 1997 Aug 7; 337 (6): 435-9
16. Mechoulam R, Vogel Z, Barg J. CNS cannabinoid receptors: role and therapeutic implications for CNS disorders. CNS Drugs 1994; 2 (4): 255-60
17. Devane WA. New dawn of cannabinoid pharmacology. Trends Pharmacol Sci 1994 Feb; 15 (2): 40-1
18. Devane WA, Dysarz III FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988 Nov; 34 (5): 605-13
19. Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998 Aug; 19 (8): 373-81
20. Jeon YJ, Yang KH, Pulaski JT, et al. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol 1996 Aug; 50 (2): 334-41
21. Bloom FE. Neurotransmission and the central nervous system. In: Hardmann JG, Goodman Gilman A, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 267-93
22. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996 Apr 30; 93 (9): 3984-9
23. Hampson AJ, Bornheim LM, Scanziani M, et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 1998 Feb; 70 (2): 671-6
24. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998 Sep; 54 (3): 459-62
25. Biegon A. Neuroprotective activity of HU-211, a novel non-psychotropic synthetic cannabinoid. Ann N Y Acad Sci 1995 Sep 15; 765: 314
26. Eshhar N, Striem S, Kohen R, et al. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 1995 Sep 5; 283 (1-3): 19-29
27. Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998 Jul 7; 95 (14): 8268-73
28. Mansbach RS, Rovetti CC, Winston EN, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 1996 Apr; 124 (4): 315-322
29. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21 (3): 175-85
30. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991 Nov; 40 (3): 701-8
31. Sanudo-Pena MC, Patrick SL, Patrick RL, et al. Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci Lett 1996 Mar 8; 206 (1): 21-4
32. Sanudo-Pena MC, Walker JM. Role of the subthalamic nucleus on cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 1997 Mar; 77 (3): 1635-8
33. Sanudo-Pena MC, Walker JM. Effects of intrapallidal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Synapse 1998 Jan; 28 (1): 27-32
34. Sanudo-Pena MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65 (6/7): 703-13
35. Sanudo-Pena MC, Patrick SL, Khen S, et al. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci Lett 1998 Jun 5; 248 (3): 171-4
36. Muller-Vahl KR, Kolbe H, Schneider U, et al. Cannabis in movement disorders. Forschende Komplementarmedi 1999 Oct; 6 Suppl. 3: 23-7
37. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998 Nov; 13 (6): 871-6
38. Frankel JP, Hughes A, Lees AJ, et al. Marijuana for Parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990 May; 53 (5): 436-42
39. Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998 Mar 21; 351 (9106): 851-2
40. Stix G. Herb remedy. Sci Am 1998 Sep; 279 (3): 11-12
41. Grotenhermen F. Therapeutic use of cannabis. Lancet 1998 Mar 7; 351 (9104): 758-9